NEW YORK MEDICAL COLLEGE

Second University of Minnesota Study Shows No Hydroxychloroquine Benefit in COVID-19 Fight

4 months ago

A second University of Minnesota study has found that hydroxychloroquine, an anti-malaria drug once championed by President Donald Trump, does not provide substantial benefits in treating COVID-19. The study compared outcomes of patients taking hydroxychloroquine with those taking a placebo and found no significant differences in death rates, hospitalizations, or persistent symptoms. The findings add to the growing evidence against the use of hydroxychloroquine for COVID-19 treatment.

Study Reveals Significant Sleep Disruption Among Parents of Children with Atopic Dermatitis

5 months ago

• National Health Interview Survey analysis shows 45.2% of parents with children having atopic dermatitis fail to get recommended 7 hours of sleep, compared to 37.1% of other parents. • Parents of children with eczema are 26% more likely to use sleep medications, with 13.3% reporting sleep aid use versus 9.9% in the control group. • The study, analyzing data from 2013-2018, represents over 6.1 million U.S. parents, highlighting the significant indirect health impact of pediatric atopic dermatitis on caregivers.

Individualized Treatment Strategies Key to Managing Geographic Atrophy

6 months ago

• Individualized treatment approaches, considering treatment timing and disease severity, are crucial for managing geographic atrophy (GA). • Pegcetacoplan and avacincaptad pegol are current GA treatments, with treatment frequency guided by drug effectiveness over time and patient motivation. • Monitoring for choroidal neovascularization, addressing vision loss, and patient education are essential components of GA management. • Treatment strategies may involve prioritizing the eye with better vision in bilateral GA cases, especially when the other eye has advanced vision loss.

Upadacitinib Shows Sustained Efficacy in Adolescents with Atopic Dermatitis

7 months ago

• Upadacitinib demonstrated a favorable long-term benefit-risk profile in adolescents with moderate to severe atopic dermatitis over 76 weeks across three phase III trials. • Significant reductions in Eczema Area and Severity Index (EASI-75) scores were achieved in 84-96% of adolescents treated with upadacitinib at both 15 mg and 30 mg doses. • The study met co-primary endpoints, including clear or almost clear skin and a minimum 4-point improvement in pruritus, highlighting the drug's comprehensive impact. • Adverse events were consistent with the known profile of upadacitinib, with acne and nausea being the most common, and no new safety signals were identified.

FDA Approves Cobenfy, a Novel Schizophrenia Treatment Targeting Cholinergic Receptors

8 months ago

• The FDA has approved Cobenfy (xanomeline and trospium chloride) as the first new class of drug for schizophrenia in over 30 years, offering a novel approach to treatment. • Cobenfy targets muscarinic receptors, unlike traditional antipsychotics that focus on dopamine, potentially reducing side effects like weight gain and movement disorders. • Clinical trials demonstrated Cobenfy significantly reduced schizophrenia symptoms compared to placebo, marking a transformative moment in managing this challenging condition. • Expected to launch in late October, Cobenfy offers a new option for adults with schizophrenia, with ongoing studies exploring its potential in Alzheimer's psychosis and other conditions.

Bio-Path Holdings Advances in Clinical Trials and Expands into Obesity Treatment

10 months ago

Bio-Path Holdings, Inc. has made significant progress in its clinical trials for cancer treatments and is preparing to explore the use of its drug prexigebersen for obesity and obesity-related cancers. The company has developed molecular biomarkers to improve treatment outcomes and is advancing its DNAbilize platform across multiple indications.